Recent Finacing
Recent Raise
Ivantis develops and commercializes the Hydrus Microstent, a minimally invasive implant that opens the trabecular meshwork and scaffolds Schlemm’s canal to lower intraocular pressure in cataract and glaucoma surgery.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors